Analyst Price Target is $3.00
▲ +554.16% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cadrenal Therapeutics in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 554.16% upside from the last price of $0.46.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Cadrenal Therapeutics. This Buy consensus rating has held steady for over two years.